Detalhe da pesquisa
1.
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.
Cancer
; 127(18): 3413-3421, 2021 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34181755
2.
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies.
Haematologica
; 106(4): 1079-1085, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32107329
3.
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
Br J Haematol
; 188(6): 907-917, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31898319
4.
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.
Haematologica
; 105(1): 193-200, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31221778
5.
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
Haematologica
; 105(4): 1074-1080, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31248973
6.
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies.
Haematologica
; 104(8): 1640-1647, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30733270
7.
PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression.
Ann Hematol
; 98(7): 1713-1720, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31053880
8.
Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation.
Biol Blood Marrow Transplant
; 24(2): 406-409, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29032267
9.
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.
Blood
; 127(9): 1102-8, 2016 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26729895
10.
Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis.
Biol Blood Marrow Transplant
; 23(9): 1549-1554, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28499937
11.
Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles.
Cancer
; 123(19): 3701-3708, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28542843
12.
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study.
Blood
; 124(1): 63-9, 2014 Jul 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-24855212
13.
The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
Biol Blood Marrow Transplant
; 21(6): 1068-73, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25754658
14.
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Blood
; 122(16): 2799-806, 2013 Oct 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-23954889
15.
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
Blood
; 122(8): 1376-83, 2013 Aug 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-23775712
16.
Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation.
Biol Blood Marrow Transplant
; 20(6): 885-90, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24583412
17.
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.
Am J Hematol
; 89(12): 1085-91, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25159313
18.
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation.
Biol Blood Marrow Transplant
; 19(3): 424-8, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23142330
19.
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry.
Biol Blood Marrow Transplant
; 19(6): 940-8, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23538113
20.
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
Blood
; 118(22): 5759-66, 2011 Nov 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-21951682